5 million and growing: scaling Granudacyn® production in Salzburg
Mölnlycke® has reached a significant milestone with the production of 5 million units of its Granudacyn® wound irrigation solution at its manufacturing site in Salzburg, Austria, reflecting strong and sustained global demand for advanced wound cleansing solutions.
“The consistent growth we’ve seen for Granudacyn® enables us to take a long-term, targeted approach to expanding our manufacturing capacity,” said Kevin Sands, General Manager of the Salzburg site. “By optimising processes, investing in equipment and applying lean principles, we are increasing output while maintaining the highest standards of quality and reliability.”
Mölnlycke acquired the Salzburg factory in October 2024 after more than five years of collaboration with its previous owners. Since then, it has been successfully integrated into Mölnlycke’s global manufacturing network of 16 sites in 11 countries, with investments in systems, operational excellence and cross-functional collaboration driving greater efficiency, scalability and growth.
Granudacyn® is a biocompatible, non-cytotoxic wound irrigation solution designed to safely cleanse, irrigate and moisten a wide range of acute, chronic and contaminated wounds. Using hypochlorous acid-based technology, it supports wound healing while ensuring microbial purity of the solution and ease of use. The product is suitable for a broad range of indications, including pressure injuries, leg and foot ulcers, burns (1st and 2nd degree) and surgical wounds.
Today, Granudacyn® is available in 54 markets worldwide, having expanded significantly beyond its European origins. Commercial momentum continues to build and, following FDA clearance, Granudacyn® is now being introduced in the United States, with further market expansion planned.
“Granudacyn® plays an important role in opening up broader conversations around modern wound care and our wider portfolio,” said Giuseppe Conti, Global Product Manager for Granudacyn®. “Its flexibility across multiple wound types, combined with strong clinical confidence, has driven adoption across a growing number of markets.”
With production continuing to scale, Mölnlycke remains committed to supporting healthcare professionals worldwide with reliable access to high-quality wound care solutions that reduce the burden of wounds, improve patient outcomes and enhance clinical efficiency.
Latest news
-
Mölnlycke Health Care announces Andreas Johansson as Interim Chief Financial Officer
Gothenburg, Sweden. Wednesday 15 April 2026. Mölnlycke Health Care announces today the appointment of Andreas Johansson as Interim Chief Financial Officer (CFO), with immediate effect.
-
Mölnlycke® celebrates 100 million ProcedurePak® trays - advancing operating room efficiency worldwide
Gothenburg, Sweden. 27 January 2026. Mölnlycke Health Care, a global leader in Medtech, headquarted in Gothenburg, Sweden, is celebrating the production of 100 million ProcedurePak® trays at the company's production sites in the Czech Republic.
-
Mölnlycke donates patent to spark innovation in sustainable healthcare
Gothenburg, Sweden. 12 November 2025. Mölnlycke Health Care, a global leader in MedTech, is the first company to donate a patent to SKF’s groundbreaking digital platform, The Patent Bay – taking bold action to harness collaboration and accelerate innovation in sustainable healthcare.
-
Mölnlycke Health Care’s global headquarters ranked number one workplace in Sweden and top 20 globally in Leesman workplace experience survey
Gothenburg, Sweden, 15 October 2025 Mölnlycke® Health Care is proud to announce that its global headquarters have placed number one in Sweden, and top 20 globally, in the prestigious Leesman® Index, a benchmark survey measuring workplace experience across thousands of organisations worldwide.
-
Mölnlycke establishes first wound care manufacturing site in China
Changshu, China, and Gothenburg, Sweden. 5 November 2025. Mölnlycke® Health Care, a global leader in MedTech, headquartered in Gothenburg, Sweden, is celebrating the commencement of its new wound care manufacturing site in Changshu, China. This strategic investment marks a milestone in Mölnlycke’s growth journey and the beginning of localised manufacturing in one of the world’s fastest-growing MedTech markets.
-
Mölnlycke Health Care breaks ground on $135 million expansion of Wound Care manufacturing facility in Brunswick, Maine
Brunswick, Maine, USA and Gothenburg, Sweden. 23 September 2025. Mölnlycke® Health Care, a global leader in MedTech, headquartered in Gothenburg, Sweden, today celebrates the groundbreaking of a major expansion to its wound care manufacturing capacity in Brunswick, Maine. This milestone marks the beginning of a $135 million investment aimed at significantly increasing Mölnlycke’s manufacturing capacity in the United States.
-
New study highlights the importance of double gloving with indicator systems
A new peer-reviewed study published in the Journal of Hospital Infection underscores the critical role of double gloving and indicator systems in reducing the risk of undetected glove breaches during surgery.
-
Mölnlycke Health Care AB: CEO, Zlatko Rihter, announces resignation, Guillaume Joucla appointed interim CEO
Tue, Mar 24, 2026 Today, it was announced that Zlatko Rihter, CEO of Mölnlycke Health Care, has informed the Board of Directors of his decision to resign. Following his decision, Guillaume Joucla, Chief Financial Officer, has been appointed interim CEO of Mölnlycke Health Care. Mölnlycke’s Board has initiated the recruitment process for a permanent CEO.
-
High burnout among operating room staff poses significant risk to patient safety—new review reveals
Gothenburg, Sweden. 17 September 2025. A new narrative review published in the current issue of Journal of Patient Safety, titled ’Putting Patients at Risk: The Effect of Health Care Provider Burnout on Patient Care in the Operating Room’ reveals alarmingly high levels of burnout among healthcare workers in operating rooms (ORs) and warns of the serious implications for staff well-being, care quality and ultimately patient safety.